Aaron T. Gerds

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 380 citations · Full text

Medicine, Hematology, Pharmacology +13

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Michael R. Savona, Luca Malcovati, Rami S. Komrokji et al. · Blood · 2015 · 196 citations · Full text

Medicine, Hematology, Oncology +15

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS

Aaron T. Gerds, Ted Gooley, Elihu H. Estey et al. · Biology of Blood and Marrow Transplantation · 2012 · 176 citations · Full text

Medicine, Oncology, Chemotherapy +15